Polyethylene glycol based prodrug of adrenomedullin and use thereof

Provided is a polyethylene glycol (PEG) based prodrug of adrenomedullin of formula (I), where the variables are as defined in the specification. An exemplified prodrug is O-{ [(3S)-3-Amino-4-({ (2R)-1-amino-3-[(2,5-dioxo-1-{ 3-oxo-3-[(2-{ w-methoxy-poly-oxyethylen[40kDa]} ethyl)amino]propyl} pyrroli...

Full description

Saved in:
Bibliographic Details
Main Authors WUNDER FRANK, KÖBBERLING JOHANNES, SCHOHE-LOOP RUDOLF, REDLICH GORDEN, KNORR ANDREAS, WITTROCK SVEN, LERCHEN HANS-GEORG, MARLEY JULY, FLAMME INGO, GRIEBENOW NILS, KÖLLNBERGER MARIA, PRITCHARD IAIN
Format Patent
LanguageEnglish
Published 24.12.2015
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided is a polyethylene glycol (PEG) based prodrug of adrenomedullin of formula (I), where the variables are as defined in the specification. An exemplified prodrug is O-{ [(3S)-3-Amino-4-({ (2R)-1-amino-3-[(2,5-dioxo-1-{ 3-oxo-3-[(2-{ w-methoxy-poly-oxyethylen[40kDa]} ethyl)amino]propyl} pyrrolidin-3-yl)sulfanyl]-1-oxopropan-2-yl} amino )-4-oxobutyl] carbamoyl} -L-tyrosyl-adrenomedullin(2-52). Further provided are processes for its preparation and its use in the treatment of cardiovascular, edematous and/or inflammatory disorders.
Bibliography:Application Number: NZ20120622997